Genprex

Monthly Archives: March 2019

Thermo Fisher and Brammer Bio Deal Illustrates Rapid Growth for Gene Therapy

Thermo Fisher recently announced it is buying Brammer Bio, which provides viral vector manufacturing services for gene and cell therapy companies. This acquisition is one of the many we have seen recently, as several other large pharmaceutical companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, including Roche’s acquisition of Spark Therapeutics, Biogen’s buying of Nightstar Therapeutics and Pfizer’s purchase of Vivet Therapeutics….

Read More

Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019….

Read More

IASLC 2019: Bringing Together Collaboration, Science and Hope for the Future

Last month, Genprex’s President and Chief Operating Officer, Julien Pham, attended the IASLC 2019 Targeted Therapies of Lung Cancer Meeting in Santa Monica, California. This meeting brought together a variety of key players working on the newest therapies for lung cancer including researchers, oncologists, physicians, patient advocacy groups and even clinical-stage companies, such as Genprex….

Read More

Gene Therapy Now Coming into the Mainstream as Treatment Option for Serious Diseases

Roche’s acquisition of Spark Therapeutics confirms that gene therapy has finally made its debut as a treatment option for serious diseases

Chemotherapy, radiation, and more recently, immunotherapy have been the primary treatments for patients with cancer, and there has been little progress in terms of “huge medical breakthroughs” for cancer treatment for many years.  …

Read More